Orforglipron
InvestigationalThe first oral small-molecule (non-peptide) GLP-1 receptor agonist. NDA submitted to FDA. ATTAIN trials showed 11.2% weight loss at 72 weeks. No food/water restrictions unlike oral semaglutide. Phase 3 data in 9,000+ patients.
LY3502970 · OWL833
18 human studies
- Preclinical
- 10%
- Clinical
- 90%
Based on 20 cited sources
clinically demonstrated · high confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 85: 1A 30 (>=2 independent multinational double-blind Phase 3 RCTs — ATTAIN-1 40960239 N=3,127, ATTAIN-2, ACHIEVE-2 42259339, ACHIEVE-5 42251769); 1B 21 (multiple low-RoB placebo/active-controlled RCTs plus moderate-confidence living NMAs); 1C 15 (total human N >>1,000, Phase 3 pooled hepatic set 42338042 N=11,220, narrow CIs); 1D 14 (direct obesity/T2D population, oral route, weight/HbA1c outcomes); 1E 5 (modest preclinical program — Sloop 39693407 plus a few animal/in-vitro studies). Mechanism 96: 2A 40 (GLP-1R high-affinity binding Ki=1 nM, cAMP functional confirmation, and CRISPR-sensitized rat GLP-1R knock-in confirming target engagement — 39693407); 2B 28 (full GLP-1R->Gs->cAMP->physiology chain, textbook class pathway); 2C 18 (monotonic dose-response across Phase 1/2/3 and in-vivo); 2D 10 (confirmed in in-vivo mammalian models). Plausibility 92: 3A 34 (mechanism->surrogate->clinical chain supported for weight/glycemia; hard CV outcomes pending ACHIEVE-CVOT); 3B 24 (fully coherent with GLP-1 pathophysiology); 3C 20 (multiple same-class agents — semaglutide, tirzepatide, liraglutide — reliably produce the effect); 3D 14 (tightly scoped metabolic claim). Global Coverage 63: 4A 20 (single sponsor Eli Lilly but multi-country/multi-site, now synthesized by independent academic NMAs); 4B 20 (US, Brazil, China, Japan, Romania, Canada, Spain, Saudi Arabia, and more); 4C 18 (~20-plus studies, broad and rapidly growing); 4D 5 (NDA submitted / FDA Priority Review — under formal regulatory investigation, not yet approved anywhere). Community Experience 32: 5A 14 (broad but speculative pre-launch discussion); 5B 4 (<1 year, not marketed); 5C 8 (consistent anticipation themes but no actual usage experience); 5D 6 (no substantial real-world exposure yet). Effectiveness basis clinical (high): ATTAIN-1 11.2% vs 2.1% placebo at 72 weeks (E1 26 large effect; E2 23 far exceeds ~5% MCID, 36% achieved >=15% / 18% >=20%; E3 12 weight is functional/ near-patient-relevant, CV morbidity-mortality pending; E4 22 top-tier among oral agents with ACHIEVE-2 head-to-head superiority over dapagliflozin, though injectable semaglutide 7.2mg and tirzepatide remain superior).
Orforglipron is a first-in-class oral small-molecule GLP-1 receptor agonist with robust Phase 3 clinical evidence.
How It Works (Simplified)
Orforglipron achieves similar metabolic effects to injectable GLP-1 drugs, but in a convenient oral pill:
Activates GLP-1 receptors with strong cAMP signaling but minimal beta-arrestin recruitment, potentially reducing receptor desensitization.
Acts on hypothalamic GLP-1 receptors to reduce hunger signals, leading to decreased caloric intake and sustained weight loss.
Enhances glucose-dependent insulin secretion from pancreatic beta cells, improving blood sugar control without hypoglycemia risk.
Unlike peptide GLP-1 drugs, this small molecule survives stomach acid and absorbs efficiently without food restrictions.
Key Research: Sloop KW et al. (Sci Transl Med 2024) characterized the pharmacological basis for non-peptide GLP-1R agonism by orforglipron, showing high-affinity, selective receptor binding with negligible beta-arrestin recruitment. PMID:39693407
Phase 3 Results & FDA Review (2025-2026)
ATTAIN Clinical Program: The Phase 3 ATTAIN (obesity; ATTAIN-1, ATTAIN-2) and ACHIEVE (type 2 diabetes; ACHIEVE-2, ACHIEVE-3, ACHIEVE-5) programs demonstrated clinically significant weight loss and glycemic improvement with orforglipron, a first-in-class oral non-peptide GLP-1 receptor agonist.
Head-to-Head Data: A head-to-head comparison with oral semaglutide published in The Lancet (February 2026) provided direct comparative efficacy data, positioning orforglipron competitively in the oral GLP-1 landscape.
Regulatory Status: Eli Lilly submitted orforglipron for FDA review with Priority Review designation, with a regulatory decision expected in 2026. If approved, it would be the first non-peptide oral GLP-1 receptor agonist, potentially offering advantages in manufacturing scalability and cost.
Important Limitations
- Long-term cardiovascular outcomes data still pending (ACHIEVE-CVOT ongoing)
- Not yet FDA-approved (NDA submitted, Priority Review granted)
- GI side effects occur in 25-35% of patients (similar to injectable GLP-1 class)
- Daily dosing required (unlike weekly injectable alternatives)
- Optimal use in combination with lifestyle modifications
Reported positives
- Oral GLP-1 pill format generating significant community excitement
- Potential to democratize access vs injectable alternatives
- Daily pill convenience preferred by needle-averse community members
- FDA Priority Review status builds confidence
Reported negatives
- Not yet available — all discussion is speculative
- Daily dosing less convenient than weekly injectables
- Lower efficacy than leading injectable options in trials
- Cost and insurance coverage unknown
“High anticipation in weight management communities. Oral format could be a game-changer for access.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
Initial titration period. GI side effects (nausea, vomiting, diarrhea) most common during dose escalation. Appetite reduction typically begins within first weeks.
PMID:37351564Progressive weight loss observed. Phase 2 data showed approximately 5-7% weight loss by week 12 at higher doses. Glycemic improvements evident in diabetic patients.
PMID:37351564Continued weight loss trajectory. Phase 2 showed 9.4% to 14.7% weight loss across doses at 36 weeks (vs 2.3% placebo). GI tolerability generally improves after initial weeks.
PMID:37351564Phase 3 ATTAIN trials demonstrated 11.2% weight loss at 72 weeks in obesity (ATTAIN-1) and 9.6% in obesity with T2D (ATTAIN-2). Sustained metabolic benefits observed.
PMID:40960239Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (5 indicators)
Warning Signs (4 indicators)
Bad Signs (5 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
5-Amino-1mq
CompatibleDifferent mechanisms of action. 5-Amino-1MQ inhibits NNMT for metabolic effects while orforglipron acts on GLP-1R. No known interactions.
Semaglutide
CautionBoth are GLP-1 receptor agonists. Concurrent use would result in redundant mechanisms and increased risk of GI side effects. Not recommended to combine.
BPC-157
CautionBoth affect GI function. BPC-157 is gastroprotective while orforglipron slows gastric emptying. Monitor GI symptoms if combined.
Tirzepatide
AvoidTirzepatide is a dual GIP/GLP-1 agonist. Combining with orforglipron would cause overlapping GLP-1 receptor activation. Contraindicated.
Retatrutide
AvoidRetatrutide is a triple GIP/GLP-1/glucagon agonist. Concurrent GLP-1 receptor activation contraindicated.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Orforglipron
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium · NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191 · hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833 · NN9838
A long-acting amylin analog developed by Novo Nordisk for weight management. Studied in Phase 3 trials as CagriSema (combination with semaglutide). The Phase 3 REDEFINE 1 trial showed -20.4% weight loss with cagrilintide-semaglutide versus -3.0% with placebo at 68 weeks.
CagriSema
Cagrilintide-Semaglutide · NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.